Pemetrexed as first-line therapy for non-squamous non-small cell lung cancer

Serena Ricciardi; Silverio Tomao; Filippo De Marinis

Pemetrexed as first-line therapy for non-squamous non-small cell lung cancer

Serena Ricciardi, Silverio Tomao, Filippo De Marinis

Istituto Europeo di Oncologia

Research output: Contribution to journal › Article › peer-review

Abstract

Pemetrexed is a new cytotoxic agent that is a standard of care for the second-line treatment of non-small cell lung cancer (NSCLC) and in combination with cisplatin in treatment of malignat pleural mesothelioma. It has been studied in numerous phase II and III trials in combination with different drugs or as single agent. Recently, pemetrexed has been approved in combination with cisplatin for the first-line treatment of patients with locally advanced or metastatic NSCLC other than squamous cell histology. The toxicity is acceptable and similar to that of other NSCLC regimens. The postinduction maintenance therapy with pemetrexed is being evaluated in a phase III, double-blind, placebo-controlled study.

Original language	English
Pages (from-to)	781-787
Number of pages	7
Journal	Therapeutics and Clinical Risk Management
Volume	5
Issue number	1
Publication status	Published - 2009

Keywords

First-line setting
Non-small cell lung cancer
Non-squamous carcinoma
Pemetrexed

ASJC Scopus subject areas

Pharmacology (medical)
Medicine(all)
Pharmacology, Toxicology and Pharmaceutics(all)
Safety Research
Chemical Health and Safety

Fingerprint Dive into the research topics of 'Pemetrexed as first-line therapy for non-squamous non-small cell lung cancer'. Together they form a unique fingerprint.

Cite this

@article{ad4bc70b1ef14789b219eaa5e0a80810,

title = "Pemetrexed as first-line therapy for non-squamous non-small cell lung cancer",

abstract = "Pemetrexed is a new cytotoxic agent that is a standard of care for the second-line treatment of non-small cell lung cancer (NSCLC) and in combination with cisplatin in treatment of malignat pleural mesothelioma. It has been studied in numerous phase II and III trials in combination with different drugs or as single agent. Recently, pemetrexed has been approved in combination with cisplatin for the first-line treatment of patients with locally advanced or metastatic NSCLC other than squamous cell histology. The toxicity is acceptable and similar to that of other NSCLC regimens. The postinduction maintenance therapy with pemetrexed is being evaluated in a phase III, double-blind, placebo-controlled study.",

keywords = "First-line setting, Non-small cell lung cancer, Non-squamous carcinoma, Pemetrexed",

author = "Serena Ricciardi and Silverio Tomao and {De Marinis}, Filippo",

year = "2009",

language = "English",

volume = "5",

pages = "781--787",

journal = "Therapeutics and Clinical Risk Management",

issn = "1176-6336",

publisher = "Dove Medical Press Ltd.",

number = "1",

}

TY - JOUR

T1 - Pemetrexed as first-line therapy for non-squamous non-small cell lung cancer

AU - Ricciardi, Serena

AU - Tomao, Silverio

AU - De Marinis, Filippo

PY - 2009

Y1 - 2009

N2 - Pemetrexed is a new cytotoxic agent that is a standard of care for the second-line treatment of non-small cell lung cancer (NSCLC) and in combination with cisplatin in treatment of malignat pleural mesothelioma. It has been studied in numerous phase II and III trials in combination with different drugs or as single agent. Recently, pemetrexed has been approved in combination with cisplatin for the first-line treatment of patients with locally advanced or metastatic NSCLC other than squamous cell histology. The toxicity is acceptable and similar to that of other NSCLC regimens. The postinduction maintenance therapy with pemetrexed is being evaluated in a phase III, double-blind, placebo-controlled study.

AB - Pemetrexed is a new cytotoxic agent that is a standard of care for the second-line treatment of non-small cell lung cancer (NSCLC) and in combination with cisplatin in treatment of malignat pleural mesothelioma. It has been studied in numerous phase II and III trials in combination with different drugs or as single agent. Recently, pemetrexed has been approved in combination with cisplatin for the first-line treatment of patients with locally advanced or metastatic NSCLC other than squamous cell histology. The toxicity is acceptable and similar to that of other NSCLC regimens. The postinduction maintenance therapy with pemetrexed is being evaluated in a phase III, double-blind, placebo-controlled study.

KW - First-line setting

KW - Non-small cell lung cancer

KW - Non-squamous carcinoma

KW - Pemetrexed

UR - http://www.scopus.com/inward/record.url?scp=77949458607&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949458607&partnerID=8YFLogxK

M3 - Article

C2 - 19851525

AN - SCOPUS:77949458607

VL - 5

SP - 781

EP - 787

JO - Therapeutics and Clinical Risk Management

JF - Therapeutics and Clinical Risk Management

SN - 1176-6336

IS - 1

ER -